nordisk’s

Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026

Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026    …

2 weeks ago

Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

9 months ago